<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="135474"><SearchResults><Trial Id="339289"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN COLORECTAL CANCER</Identifier><Identifier>NCT03524274</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>center, the investigators will be planing to recruit for 90 patients with advanced colorectal &lt;b&gt;cancer&lt;/b&gt;, and all patients will be divided into three groups: Group 1: patients...anti-MUC1 BiTE cytokine induced killer cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical together with cryotherapy. The maximum tumor length &amp;gt;/= 2 cm, cool down... Medium/above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study Of Activated Cytokine Induced Killer Armed With Bispecific Antibody For Advanced Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease</PatientSegment><PatientSegment>Colorectal tumor - Subjects with resectable colorectal cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="336775"><Indications><Indication>Metastatic lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-03-27T00:00:00Z</DateEnd><DateStart>2018-03-27T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN LUNG CANCER</Identifier><Identifier>NCT03501056</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators plan to recruit for 90 patients with advanced lung &lt;b&gt;cancer&lt;/b&gt;. This study consist of three treatment arms: Arm 1 (cryotherapy): patients with the...antibody of anti-CD3/MUC1 ; anti-CD3/anti-MUC1 T-cell engager CIK cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical) will be administered. Arm 3 (no Intervention: conventional...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma„ÄÅmyeloma,and patients are using immunosuppressant Systemic</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 3 years</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Evaluation by MRI/CT scan</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-Induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Resectable/Operable Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-27T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="342813"><Indications><Indication>Metastatic stomach cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN GASTRIC CANCER</Identifier><Identifier>NCT03554395</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>single-center, the investigators plan to recruit for 90 patients with advanced gastric &lt;b&gt;cancer&lt;/b&gt;,and all patients are divided into three groups: one group will receive...-CD3/MUC1; anti-CD3/anti-MUC1 T-cell engager CIK cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical. Group 3 (no intervention: conventional therapy): in this...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients are using immunosuppressant</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Disease Relapse/Recurrence - Assessment of relapse rate</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Resectable Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Stage IV Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Stomach tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="339277"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN BREAST CANCER</Identifier><Identifier>NCT03524261</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>single-center, the investigators will plan to recruit for 90 patients with advanced breast &lt;b&gt;cancer&lt;/b&gt;, and all patients will be divided into three groups: Group 1: patients... Medium/above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients are using immunosuppressant... Age 18 to 75 years The patient is diagnosed as advanced breast &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10 mm</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of circulating tumor cell response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study Of Activated Cytokine Induced Killer Armed With Bispecific Antibody For Advanced Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="337607"><Indications><Indication>Metastatic pancreas cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-12T00:00:00Z</DateEnd><DateStart>2018-04-12T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN PANCREATIC CANCER</Identifier><Identifier>NCT03509298</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators will plan to recruit 90 patients with advanced pancreatic &lt;b&gt;cancer&lt;/b&gt;, and all patients are divided into three groups. One group will receive cryotherapy...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma,and patients are using immunosuppressant Systemic... Age 18 to 75 years old The patient is diagnosed as advanced pancreatic &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pancreas tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pancreas tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment of symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="341183"><Indications><Indication>Metastatic renal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-10T00:00:00Z</DateEnd><DateStart>2018-04-10T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN KIDNEY CANCER</Identifier><Identifier>NCT03540199</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>CIK cells (activated by PD-1 inhibitor) with bispecific antibody of anti-CD3-MUC1; anti-CD3/anti-MUC1 T-cell engager CIK cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceuticaland cryotherapy...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma and patients are using immunosuppressant Systemic... Age18 to 75 years old The patient is diagnosed as advanced kidney &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10mm</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Biomarkers - Assessment of other tumor markers</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Other Measures of Response - Assessment of best response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Other/Unspecified Efficacy Parameters</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of duration of objective/overall response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="34162"><Indications><Indication>Bladder cancer</Indication><Indication>Cancer</Indication><Indication>Esophagus tumor</Indication><Indication>Hormone refractory prostate cancer</Indication><Indication>Non-small-cell lung cancer</Indication><Indication>Sarcoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>DNA vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Transdermal formulation</Technology><Technology>Transdermal high velocity particle formulation</Technology></Technologies><CompaniesCollaborator><Company>Columbia University</Company><Company>MD Anderson Cancer Center</Company><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ludwig Institute for Cancer Research</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-24T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-0013</Identifier><Identifier>LUD2002-006</Identifier><Identifier>NCT00199849</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NY-ESO-1 DNA vaccine (cancer), Ludwig Institute/PowderMed alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>LAGE-1 antigen would be assigned to cohorts. NY-ESO-1 Plasmid DNA (pPJV7611) &lt;b&gt;cancer&lt;/b&gt; vaccine would be administered by PMED at a pressure of 500 psi using the XR...skin &lt;b&gt;cancer&lt;/b&gt;, cervical carcinoma in situ and incidental prostate &lt;b&gt;cancer&lt;/b&gt; on radical cystoprostatectomy specimen Mental impairment, in the opinion of...breast &lt;b&gt;cancer&lt;/b&gt;, bladder &lt;b&gt;cancer&lt;/b&gt;, hepatocellular &lt;b&gt;cancer&lt;/b&gt;, synovial sarcoma, leiomyosarcoma, head and neck, lung &lt;b&gt;cancer&lt;/b&gt;, esophageal, ovarian, neuroblastoma</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Antibodies</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Chemotherapy Induced Toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of grade 1 toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of grade 2 toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of immunological markers</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of dermatologic manifestations</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of subject withdrawals</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events (AE) &amp; serious adverse events (SAEs)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of antibody titers</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of cellular response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables - Assessment of PSA response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of progressive disease</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 1 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 2 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of treatment emergent adverse events</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Metastatic Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage IV Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Advanced/Metastatic Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Stage IV Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Neuroblastoma - Subjects with INSS Stage 4 Neuroblastoma</PatientSegment><PatientSegment>Neuroblastoma - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Cancer Resistant or Refractory to Non-Platinum Therapies</PatientSegment><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Advanced/Metastatic Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Leiomyosarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Synovial Sarcoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Nasser K Altorki, MD</Name><Name>Padmanee Sharma, MD PhD</Name></ContactNames></Trial><Trial Id="321009"><Indications><Indication>Metastatic renal cell carcinoma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Metastasis inhibitor</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Jinan University (Guangdong)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2017-11-30T00:00:00Z</DateStart><Identifiers><Identifier>KIDNEY CANCER MV</Identifier><Identifier>NCT03357289</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mix vaccine (sc, renal tumor), Fuda Cancer Hospital/Jinan University alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>survival (PFS) and overall survival (OS). Group 1: in this group, the patients will receive mix vaccine (sc, renal tumor), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan...guidelines or the patient refuses standard therapies after &lt;b&gt;cancer&lt;/b&gt; recurrence Body tumor 1 to 6, the maximum tumor length&amp;lt; 2 cm KPS &amp;gt;/= 70, lifespan &amp;gt; 6 months...is to evaluate the safety and efficacy of mix vaccine (sc, renal tumor), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan University to small metastasis of kidney &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Biomarkers - Assessment of other tumor markers</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Immune Response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 3 months</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 1 year</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Renal cell carcinoma - Hematological Assessments</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments - MRI assessment/changes</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments - PET/CT scan assessment/changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Mix Vaccine for Metastatic Kidney Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Recurrent/ Relapsed Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with TNM Stage IV Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Treatment Resistant Disease - Subjects resistant/refractory to standard treatment</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jibing Chen, MD, PhD</Name></ContactNames></Trial><Trial Id="338912"><Indications><Indication>Bladder cancer</Indication><Indication>Transitional cell carcinoma</Indication></Indications><CompaniesCollaborator><Company>Johns Hopkins University</Company><Company>National Institutes of Health</Company></CompaniesCollaborator><CompaniesSponsor><Company>H Lee Moffitt Cancer Center and Research Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-04T00:00:00Z</DateChangeLast><DateEnd>2022-12-31T00:00:00Z</DateEnd><DateStart>2019-09-30T00:00:00Z</DateStart><Identifiers><Identifier>MCC-19574</Identifier><Identifier>NCT03517995</Identifier></Identifiers><InterventionsControlDisplay><Intervention>bladder cancer surgery alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Prostaphane (Nutinov Labs, France) alone</Intervention><Intervention>bladder cancer surgery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>135</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>bladder &lt;b&gt;cancer&lt;/b&gt; to when they undergo a surgical procedure for the treatment or removal of their bladder &lt;b&gt;cancer&lt;/b&gt;. The surgical procedure will be done...from when participants will be diagnosed with bladder &lt;b&gt;cancer&lt;/b&gt; to when they undergo a surgical procedure for the treatment or removal of their bladder &lt;b&gt;cancer&lt;/b&gt;. The...other &lt;b&gt;cancer&lt;/b&gt;, excluding non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; Any treatment for the bladder tumor other than intravesical therapy Prior treatment with</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of apoptosis</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of toxicity</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Bladder cancer - Clinical Assessments</EndpointIndex><EndpointIndex>Bladder cancer - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Bladder cancer - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Bladder cancer - Protocol Specified Other Endpoints - Assessment of Efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Resectable Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Blood cells </BiomarkerName><BiomarkerName> Caspase-3 </BiomarkerName><BiomarkerName> DNA replication licensing factor MCM2 </BiomarkerName><BiomarkerName> Epoxide hydrolase 2 </BiomarkerName><BiomarkerName> Glucuronosyltransferase </BiomarkerName><BiomarkerName> NADP </BiomarkerName><BiomarkerName> Nuclear factor erythroid 2 related factor 2 </BiomarkerName><BiomarkerName> Transcription factor p65</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Cesar Ercole, M.D.</Name><Name>Kayoko Kennedy</Name><Name>Nagi Kumar, Ph.D</Name><Name>Nagi Kumar, Ph.D.</Name></ContactNames></Trial><Trial Id="240229"><Indications><Indication>Metastatic breast cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-08-15T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>BREAST CANCER CAR-T 001</Identifier><Identifier>NCT02547961</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HER-2-targeting CAR T cells alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>breast &lt;b&gt;cancer&lt;/b&gt;. Autologous T cells would be gene-engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients would be... Chemotherapy refractory Her2 positive breast &lt;b&gt;cancer&lt;/b&gt; Relapsed patients after anti-Her2 using antibody or kinase inhibitor therapy Patients must be &amp;gt;/= 18 years... The purpose of this study was to evaluate the safety and efficacy of HER2-CAR-T cell infusion for advanced HER2 positive breast &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Chimeric Antigen Receptor-Modified T Cells for Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-08-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lizhi Niu, PhD</Name></ContactNames></Trial></SearchResults></trialResultsOutput>